RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
16,08 USD
arrow_downward
-1,17%(-0,19) 1D
13 lis, 16:00:00 GMT-5 · USD
search
Wszystkie symbole
| Symbol | Cena | Zmiana | Zmiana % |
|---|
insights_autoGeneruję najważniejsze statystyki dotyczące: RARE…
Otwarcie
16,30 USD
Maks.
16,32 USD
Min.
15,85 USD
Kapitalizacja
1,64 mld
Śr. wol.
3,71 mln
Wolumen
1,68 mln
Najwyższa z 52 tyg.
39,89 USD
Minimum z 52 tyg.
12,73 USD
Zysk na akcję
-5,19 USD
Beta
0,37
Akcje w obiegu
101,92 mln
Liczba pracowników
1 tys.
Otwarcie
16,30 USD
Maks.
16,32 USD
Min.
15,85 USD
Kapitalizacja
1,64 mld
Śr. wol.
3,71 mln
Wolumen
1,68 mln
Najwyższa z 52 tyg.
39,89 USD
Minimum z 52 tyg.
12,73 USD
Zysk na akcję
-5,19 USD
Beta
0,37
Akcje w obiegu
101,92 mln
Liczba pracowników
1 tys.
Wiadomości
Ze źródeł internetowych i od partnerskich agencji informacyjnych
TradingKey
·
6 godzin temu
S&P 500 Forecast: Index Poised to Retest Record High in November After 500-Point Pullback, Biggest Daily Gain in Nearly Seven Months
Foreign Policy Journal
·
5 godzin temu
Dow Jones Industrial Average (DJIA) Stays Green While Nasdaq Tumbles Nearly 1% In Sharp Rotation Trade
24/7 Wall St.
·
9 godzin temu
He Thinks His $200,000 S&P 500 401(k) Spreads His AI Risk. Two Alphabet Share Classes Put $10,380 in One Company. A 20% Drop Could Cost Him $2,076
Traders Union
·
13 godzin temu
Michael Kantro: Institutional investors focus on stock picking as S&P 500 targets have lost relevance
Profil
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
Ultragenyx Pharmaceutical Inc – informacje
PrezesEmil Kakkis
Pracownicy1,37 tys.
Data założenia2010
Siedziba głównaNovato, Kalifornia, Stany Zjednoczone
SektorHealth Care
Branża-
Witrynaultragenyx.com